He replaces interim CEO Daniel Florin, who will resume his duties as senior vice president and CFO. We view the hire positively as it removes the near-term overhang of management uncertainty and adds a seasoned medtech veteran to the management team and board. The most recent bid on the stock was registered at $121.38.
ZBH has been the subject of a number of other reports. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet to $125.00 and set an outperform rating for the company in a research note on Tuesday, November 7th.
Among 30 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 21 have Buy rating, 2 Sell and 7 Hold. Jefferies Group restated a buy rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Edward Jones upgraded the stock to "Buy" rating in Thursday, November 9 report. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock.
According to Zimmer, Hanson (50 years old) is joining Zimmer Biomet after serving as a member of Medtronic's Executive Committee and as the Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group, where he oversaw and provided strategic direction to this approximately $9 billion business (Zimmer's revenue run rate is $7.8 billion).
Zimmer Biomet Holdings, Inc. The company has a market cap of $23,169.00, a PE ratio of 14.18, a P/E/G ratio of 1.78 and a beta of 1.15. The current ratio for ZBH is 1.50 and that of IMMU is 0.70.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks' consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. The Return on Equity ratio of Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, makes, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Following some medium-term indicators on shares of Zimmer Biomet Holdings, Inc.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Thursday, December 28th. The current P/E Ratio for Zimmer Biomet Holdings, Inc.
Several other institutional investors have also bought shares of the company. Zimmer Biomet Holdings, Inc. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider's stock worth $2,236,657,000 after buying an additional 679,080 shares during the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of Zimmer Biomet by 249.3% in the third quarter. Geneva Advisors LLC increased its position in Zimmer Biomet by 2.7% during the second quarter. Zimmer Biomet Holdings, Inc. price comparative to this fiscal earnings is 13.93x, asset price might not outperform in future. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider's stock worth $166,000 after buying an additional 66 shares during the period.
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.